Vigil Neuroscience Shares Trade in Narrow Range Ahead of Sanofi Acquisition

The investment narrative for Vigil Neuroscience is now singularly focused on its impending acquisition by pharmaceutical titan Sanofi. The biotech firm?s shares are trading near the agreed-upon buyout price of $8.00 per share, signaling strong market confidence that the transaction will be finalized.

Trading activity has become tightly range-bound, with the stock currently hovering around $8.05?just marginally above the acquisition offer. This price action reflects a market that views the deal as a near certainty. The 52-week trading window highlights this shift dramatically, with the stock having reached a high of $8.10 after plumbing a low of $1.31. The minimal spread between the current price and the offer indicates that any potential for independent share price appreciation has been effectively... Read more...